Panelists talk about how the present remedy panorama for sufferers with late-line relapsed/refractory a number of myeloma (RRMM) entails novel approaches comparable to bispecific antibodies, CAR-T cell therapies, antibody-drug conjugates and medical trials of rising brokers, with remedy choice extremely individualized primarily based on prior therapies, resistance patterns and patient-specific components like comorbidities, high quality of life issues and remedy targets.
